JOHNSON & JOHNSON Q1 2025 Filing

Filed May 7, 2025

Portfolio Value

$341.9B

Holdings

20

Report Date

Q1 2025

Filing Type

13F-HR

All Holdings (20 positions)

#StockSharesValue% PortfolioType
1
PTGXProtagonist Therapeutics Inc.
2,449,183$118.4B34.65%
2
CVRXCVRx, Inc.
4,103,430$50.2B14.68%
3
MGTXMeiraGTx Holdings plc
6,641,064$45.0B13.17%
4
LEGNLegend Biotech Corporation
814,586$27.6B8.08%
5
RAPPRapport Therapeutics, Inc.
2,498,051$25.1B7.33%
6
PRCTProcept BioRobotics Corporation
357,939$20.9B6.10%
7
NBTXNanobiotix S.A.
5,623,816$20.1B5.89%
8
CTNMContineum Therapeutics Inc.
1,979,173$13.8B4.04%
9
XNCRXencor, Inc.
748,062$8.0B2.33%
10
ARWRArrowhead Pharmaceuticals, Inc.
247,598$3.2B0.92%
11
FATEFate Therapeutics, Inc.
3,379,064$2.7B0.78%
12
RLYBRallybio Corporation
3,636,363$2.4B0.70%
13
NMRANeumora Therapeutics, Inc.
1,849,445$1.8B0.54%
14
NNOXNano-X Imaging Ltd.
158,852$793.5M0.23%
15
VORVor Biopharma, Inc.
1,074,658$771.1M0.23%
16
LYELLyell Immunopharma Inc.
823,317$442.9M0.13%
17
FLBStandard BioTools Inc
311,967$336.9M0.10%
18
TORCEURAdicet Bio, Inc.
364,472$275.2M0.08%
19
PHGEBiomX Inc.
96,866$53.8M0.02%
20
SENS1GBPSenseonics Holdings, Inc.
54,621$35.8M0.01%